Clinical Trial Update: Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg. [Phase 1]

View source ↗

Summary

Open-label Phase 1 study evaluating 24-hour gastric pH on days 1, 2, and 7 after once-daily Lavoltidine 40 mg.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Lavoltidine (lavoltidine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Gastroesophageal Reflux Disease, Reflux, Gastroesophageal | Phase 1 | Status: COMPLETED